TriangleNCT01696084 · OUTCOME
Remission Duration
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- months
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- From the date of achievement of a remission until the date of relapse or death from any cause
What was measured
Only subjects achieving CR or CRi were assessed for remission duration.
Analysis population: Intent-to-Treat (ITT) Population: All participants randomized in the study.
Groups in this outcome
Arm A (CPX-351)
Subjects are eligible to receive up to 2 inductions and up to 2 consolidations with CPX-351. The number of inductions and consolidations a subject received depended on response.
Arm B (7+3)
Subjects are eligible to receive up to 2 inductions and up to 2 consolidations with cytarabine and daunorubicin given as a 7 + 3, or 5 days of continuous infusion of cytarabine and 2 days of daunorubicin (5+2, second induction, consolidation courses) therapy. The number of inductions and consolidations a subject received depended on response.
| Group | Source count |
|---|---|
| Arm A (CPX-351) | 153 |
| Arm B (7+3) | 156 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Arm A (CPX-351) | 6.93 | Not reported | 4.60 | 9.23 | Not reported |
| Arm B (7+3) | 6.11 | Not reported | 3.45 | 8.71 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 4.60
- upper Limit
- 9.23
- value
- 6.93
- group Id
- OG001
- lower Limit
- 3.45
- upper Limit
- 8.71
- value
- 6.11
- denoms
- counts
- group Id
- OG000
- value
- 153
- group Id
- OG001
- value
- 156
- units
- Participants
- description
- Only subjects achieving CR or CRi were assessed for remission duration.
- dispersion Type
- 95% Confidence Interval
- groups
- description
- Subjects are eligible to receive up to 2 inductions and up to 2 consolidations with CPX-351. The number of inductions and consolidations a subject received depended on response.
- id
- OG000
- title
- Arm A (CPX-351)
- description
- Subjects are eligible to receive up to 2 inductions and up to 2 consolidations with cytarabine and daunorubicin given as a 7 + 3, or 5 days of continuous infusion of cytarabine and 2 days of daunorubicin (5+2, second induction, consolidation courses) therapy. The number of inductions and consolidations a subject received depended on response.
- id
- OG001
- title
- Arm B (7+3)
- param Type
- MEDIAN
- population Description
- Intent-to-Treat (ITT) Population: All participants randomized in the study.
- reporting Status
- POSTED
- time Frame
- From the date of achievement of a remission until the date of relapse or death from any cause
- title
- Remission Duration
- type
- SECONDARY
- unit Of Measure
- months
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice